The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Commentary|Videos|December 18, 2024
Translating Metabolic Therapies Into Sarcoma
Author(s)Brian A. Van Tine, MD, PhD
Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.
Advertisement
Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Advertisement
Advertisement
Trending on OncLive
1
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
2
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
3
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
4
Dr Forde on Selecting Neoadjuvant and Perioperative Immunotherapy in Resectable NSCLC
5